Journal Homepage: -www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI:10.21474/IJAR01/18437
DOI URL: http://dx.doi.org/10.21474/IJAR01/18437

RESEARCH ARTICLE

ENHANCING VIGABATRIN DELIVERY TO THE BRAIN: THE POTENTIAL OF SOLID LIPID NANOPARTICLES

Bharanidharan D.[1], Thilak B.[2] and A.C Niranjanasree[3]

1. M. Pharmacy 2nd Year Student,Department of Pharmaceutics, Faculty of Pharmacy, SRIHER(DU).
2. M. Pharmacy 2nd Year Student, Department of Pharmaceutics, Faculty of Pharmacy, SRIHER(DU).
3. Assistant Professor, Department of Pharmaceutics, Faculty of Pharmacy, SRIHER(DU), Porur, Chennai, Tamil Nadu, India.

Manuscript Info

Manuscript History
Received: 18 January 2024
Final Accepted: 21 February 2024
Published: March 2024

Key words:-
Blood-Brain Barrier, Infantile spasm, Neurological Disorders, Solid Lipid Nanoparticles, Vigabatrin

Abstract

Vigabatrin is a powerful and helpful drug for treating epilepsy and other neurological disorders. Unfortunately, because it cannot effectively cross the blood-brain barrier, its therapeutic use has been restricted. brain-blood barrier. This hinders the ability of drugs such as vigabatrin to reach their intended target region in the brain effectively. Solid lipid nanoparticles (SLNs) provide a potential solution to this problem. They are biocompatible and biodegradable, making it easier for drugs to penetrate the BBB. The effectiveness of solid lipid nanoparticles and their potential to improve vigabatrin transport to the brain is covered in this article. Furthermore, the purpose of using Solid lipid nanoparticles as drug delivery systems and the potential applications of this technology in the treatment of neurological conditions.

Introduction:-

Vigabatrin and its role in the treatment of Partial Seizures

Partial Seizures is a neurological disease defined by repeated attacks that can seriously affect the person and the quality of life. Over the years, various antiepileptic drugs (AEDs) have been developed to control and manage seizures effectively. One such drug is Vigabatrin. Vigabatrin is a potent AED that has shown promise in the treatment of epilepsy, particularly in patients with refractory seizures or who do not respond well to other medications. It activates by enhancing gamma-aminobutyric acid (GABA) levels(Anon n.d.-b)(Anon n.d.-a). In the brain, it is a neurotransmitter with inhibitory properties that aids in controlling the activity of nerve cells. Although Vigabatrin is a successful treatment, one drawback is its limited capacity to penetrate the brain-blood barrier (BBB). The blood-brain barrier functions as a barrier to keep numerous substances—including drugs—out of the brain(Chantaburanan et al. 2023)(Liang et al. 2023).

This limited penetration prevents the drug and its ability to reach the target area and exert a therapeutic effect effectively. Researchers have looked to nanotechnology, particularly SLNs, as a possible drug delivery technique to get around this restriction. Solid lipid-based colloidal particles, or SLNs, have the potential to encapsulate medications, shield them from deterioration, and increase their stability(Anon n.d.-b)(Granja et al. 2023).

These nanoparticles have special features that improve medication transport over the BBB.

Corresponding Author:- A.C Niranjanasree
Address:- Faculty of Pharmacy, SRIHER(DU), Porur, Chennai, Tamil Nadu, India.

By encapsulating vigabatrin in SLN cells, researchers were able to improve its bioavailability and target its delivery specifically to the brain. The small size of SLNs allows them to bypass the BBB through different mechanisms such as receptor-mediated transcytosis or adsorption-mediated transcytosis (Anon n.d.-a)(Karimitabar et al. 2023). This targeted approach ensures that a higher concentration of Vigabatrin reaches the brain, increasing its therapeutic effectiveness and minimizing potential side effects(Elkateb et al. 2023).

Additionally, SLNs have the benefit of continuous release, which enables the medication to be released in a regulated and sustained manner throughout time. This long-lasting profile guarantees a prolonged therapeutic impact, minimizes the need for medication administration, and enhances patient compliance(Abdelwahab et al. 2023). Vigabatrin has a crucial role in the treatment of epilepsy, but its limited penetration through the BBB is a challenge. The purpose of SLNs as drug delivery technology shows promise for improving Vigabatrin distribution to the brain. By encapsulating the drug in SLNs, researchers achieved improved bioavailability, targeted release, and sustained release, which ultimately increases the therapeutic potential of Vigabatrin in treating epilepsy.(Rahmanian-Devin et al. 2023)(Aguilera-Garrido et al. 2023)

Challenges of Delivering Vigabatrin to the Brain

Getting drugs into the brain is tough, and it is significantly more difficult with drugs like Vigabatrin. This antiepileptic drug has shown encouraging results when used to treat a range of neurological conditions, including epilepsy. However, its ability to cross the brain and produce therapeutic effects at the site of action is crucial to its utility (Sakellari et al. 2022). The blood-brain barrier is an extremely selective barrier that shields the brain from potentially dangerous chemicals. While this is crucial to maintaining brain health, it is also a major barrier to drug delivery. Like many other drugs, Vigabatrin has the challenge of crossing this barrier to reach its target in the brain.(Sakellari et al. 2023)(Ghasemiyeh and Mohammadi-Samani 2018)

In addition to the BBB, Vigabatrin also has poor solubility. It is a hydrophilic drug, which means it has low solubility in essential lipids drug delivery systems. This limited solubility further hinders its ability to reach the brain at therapeutic concentrations. In addition, Vigabatrin is susceptible to degradation and metabolism, which can reduce its bioavailability and limit its effectiveness(Satapathy and Patro 2022). These difficulties emphasize the need for novel delivery systems that can overcome these obstacles and boost Vigabatrin's transport to the brain. SLNs is considered as a viable approach for improving medication delivery to the brain(Ghasemiyeh and Mohammadi-Samani 2018).

These nanoparticles are made of biocompatible lipids and can encapsulate drugs like Vigabatrin, preserving them from degradation and increasing their solubility. SLNs' tiny size and stable structure enable them to cross the BBB through several processes, including receptor-mediated transcytosis and passive diffusion. Furthermore, SLNs may be designed to release the medication in a regulated way, resulting in sustained therapeutic levels in the brain(Bandgar et al. 2018)(Alnasser 2019). This controlled release method not only enhances Vigabatrin's pharmacokinetics but also reduces dose frequency, hence increasing compliance among patients and overall therapy results.

Vigabatrin transport to the brain offers various obstacles, including the blood-brain barrier, low solubility, and sensitivity to degradation. Solid lipid nanoparticles provide a viable answer to these issues by increasing medication solubility, preserving it from degradation, and enabling transport across the blood-brain barrier. Solid lipid nanoparticles have the efficiency to convert neurological illness therapy and enhance patient outcomes by enhancing Vigabatrin distribution to the brain(Anon 2011).

Challenges in Developing Vigabatrin Nasal Drug Delivery Systems

While the use of solid lipid nanoparticles for Vigabatrin administration shows considerable potential, various hurdles must be overcome before producing viable nasal drug delivery systems. One of the key issues is developing SLNs with optimum physicochemical characteristics. The drug-loading capacity, particle size, and surface charge of SLNs significantly impact their performance as drug carriers. Achieving the desired particle size distribution and surface charge can be challenging, as these properties are influenced by various formulation parameters, such as lipid composition, surfactant concentration, and processing techniques. Finding the proper balance of these factors is critical for ensuring the long-term viability and effectiveness of the nasal drug delivery system(Forbes et al. 2020). Another challenge lies in the characterization of SLNs.

Accurate characterization is required to determine both the performance and quality of SLNs. Dynamic light scattering, electron transmission microscopy, and FT-IR spectroscopy are routinely used methods to assess particle size, shape, and drug encapsulation effectiveness of SLNs(Uldall et al. 1991). On the other hand, the intricacy of the SLN formulations and the possibility of excipient interaction make achieving accurate and reproducible findings difficult. In addition to formulation and characterization issues, regulatory considerations must be considered in the development of Vigabatrin nasal drug delivery systems(Dimitrijevic et al. 2010)(Mueller et al. 2001).

Regulatory agencies require extensive data on the safety, efficacy, and stability of the drug delivery system before approving clinical use. Conducting preclinical and clinical studies, complying with regulatory guidelines, and addressing potential safety concerns are essential steps in the commercialization of Vigabatrin nasal delivery of drug (MacKeigan, Feja, and Gernert 2024). The development of drug Vigabatrin as nasal delivery systems using solid lipid nanoparticles is not without its challenges. Overcoming formulation and characterization challenges, as well as negotiating regulatory restrictions, are critical for successfully translating SLNs from lab to clinic. However, with continued research and innovation, these challenges can be overcome, paving the way for improved epilepsy treatment options(Faulkner and Tolman 2011).

Comparison of Vigabatrin Nasal Drug Delivery Systems with Other Routes of Administration

Vigabatrin nasal drug delivery systems including solid lipid nanoparticles provide various benefits over traditional modes of administration. The performance and advantages of drug vigabatrin as nasal delivery systems compared to drug delivery systems with other routes of administration routinely utilized for epilepsy treatment. Oral administration is the most common way of administering Vigabatrin(Loeb et al. 1992; Zaccara et al. 2013). However, this technique has significant drawbacks, including high first-pass metabolism and limited bioavailability. First-pass metabolism is process by which a medication is broken down in the liver before entering the bloodstream. This can lead to increased bioavailability and lower dosage needs. Vigabatrin is also often administered via intravenous (IV) injection. IV administration provides quick and total absorption; nevertheless, it needs healthcare experts to administer and may not be suitable for long-term usage(Sankar, Lerner, and Salamon 2010).

Nasal drug delivery, on the other hand, offers a non-invasive and patient-friendly alternative. It can be self-administered by patients, eliminating the need for the need for healthcare professionals and reducing the burden on healthcare systems. Nasal drug delivery also offers the advantage of faster onset of action compared to oral administration, making it particularly beneficial in emergencies or for patients requiring immediate seizure control(Loeb et al. 1992; Plant and Sergott 2011). In addition to oral and IV administration, intranasal drug delivery provides unique advantages specific to vigabatrin. The nasal cavity is rich in blood vessels and has a large surface area, allowing for efficient drug absorption. Moreover, the nasal mucosa contains olfactory and trigeminal nerve endings, which can facilitate direct delivery of drug to the brain.This is particularly beneficial for vigabatrin, which targets the CNS. Nasal medication administration bypasses the BBB, resulting in larger drug concentrations at the target location and better therapeutic effects. It is important to note that nasal drug delivery also has its limitations. Nasal drug absorption can be influenced by factors such as nasal mucociliary clearance, nasal congestion, and individual variations by factors such as nasal physiology. Achieving consistent and reproducible drug absorption can be challenging, requiring careful optimized formulation of nasal delivery systems(Acharya et al. 2013; Tarkase, Nimbalkar, and Kale 2017), (Garud, Singh, and Garud 2012).

Solid Lipid Nanoparticles (SLN) and their Advantages in Drug Delivery

Solid lipid nanoparticles (SLN) are a potential medication delivery technique, particularly for improving delivery to the brain. These nanoparticles comprise biocompatible lipids that create a solid matrix, enclosing the medicine within its structure. This innovative dosage form has various benefits over typical medication delivery methods. One significant benefit of SLNs is their potential to increase bioavailability of drugs by increasing its solubility. The solid lipid matrix keeps the medication stable, avoiding degradation and preserving its therapeutic potency(Calderón-Colón et al. 2015)(Fatouh, Elshafeey, and Abdelbary 2017). This is especially critical for medications with low water solubility since they frequently struggle with adequate delivery and absorption. Furthermore, SLNs enable a regulated and continuous release of the medication, ensuring a long-term therapeutic benefit. The lipid matrix functions as a barrier, regulating the pace of drug release and reducing the danger of dramatic peaks or swings in drug concentration.

This controlled-release method reduces dosage rates while increasing patient compliance. SLNs are also very biocompatible and biodegradable, making them appropriate for a variety of delivery routes, including oral,

intravenous, and intranasal. Furthermore, their tiny size allows for effective cellular absorption and transit across biological barriers, including the blood-brain barrier (Laquintana et al. 2009). This property is especially advantageous for drug delivery to the brain, as the BBB's selective permeability poses a considerable barrier to drug transport. Furthermore, SLNs may readily be surface-modified, allowing targeted drug delivery to specific cells or tissues(Robert Cronin Yung Peng, Rose Khavari 2017).

Nanoparticles may be actively targeted to specific receptors or cells by attaching ligands or antibodies to their surfaces, improving therapeutic efficacy and lowering the risk of adverse effects. Solid lipid nanoparticles (SLNs) have several benefits for medication administration, including improved distribution to the brain. Their capacity to increase solubility, give controlled release, assure biocompatibility, and allow targeted distribution makes them a viable tool in the field of drug R & D (Musielak, Feliczak-Guzik, and Nowak 2022).

Techniques and Characterization of solid lipid nanoparticles for Vigabatrin Delivery Solid lipid nanoparticles (SLNs) for Vigabatrin distribution must be prepared using a variety of approaches to ensure ideal particle size, drug encapsulation effectiveness, and stability. In this part, we'll look at some of the most prevalent ways for SLN preparation. The heat homogenization process is one of the classic ways to prepare SLN. This approach involves melting lipids and Vigabatrin together at a high temperature to produce a uniform lipid melt. This lipid melt is then mixed with an aqueous solution of surfactant at high speed or homogenized. The resultant nanoemulsion is subsequently cooled to room temperature, causing the creation of SLNs through the solidification of the lipid matrix(Bhattacharjee et al. 2020).This approach is reasonably basic and readily scaled up for commercial use.

The solvent emulsification-evaporation process is another way to prepare SLN. Vigabatrin and lipids are dissolved in an organic phase to produce a transparent solution. This solution is then dropped into an aqueous solvent containing a surfactant while vigorously stirring. The organic solvent evaporates at reduced pressure, resulting in the synthesis of SLNs. Adjusting the formulation parameters allows for fine control of particle size and drug encapsulation efficiency. Supercritical fluid technology is another novel method for preparing SLN.

Lipids and Vigabatrin are dissolved in a fluid that is supercritical, such CO_2, under high pressure. The supercritical fluid serves as a solvent, permitting the production of SLNs.One advantage of this method is that it does not require the use of organic solvents, which can cause environmental issues and harmful (Agrawal, Tatode, and Umekar 2020). Furthermore, supercritical fluid technology allows for the fabrication of SLNs with a narrow particle size distribution and excellent drug loading capacity. In recent years, the ultrasound-assisted approach of SLN preparation has grown in favor.

Lipids and Vigabatrinare suspended in a surfactant-containing aqueous medium. The dispersion is exposed to ultrasonic waves, resulting in the creation of SLNs by cavitation. Ultrasound not only helps to achieve smaller particle sizes but also improves drug encapsulation efficiency by increasing lipid matrix breakdown. The creation of solid lipid nanoparticles for Vigabatrin distribution can be accomplished using a variety of processes, including hot homogenization, solvent emulsification-evaporation, supercritical fluid technology, and ultrasound-assisted methods. The target particle size, drug encapsulation efficiency, and the process's scalability all influence the approach used(Laquintana et al. 2009). These strategies are critical in improving the formulation parameters and assuring the efficacy of Vigabatrin nasal medication delivery systems.

The performance and effectiveness of Vigabatrin nasal drug delivery systems are significantly influenced by the formulation and characterisation of solid lipid nanoparticles (SLNs)(Alnasser 2019). In this section, we will explore the key aspects of SLN formulation and the techniques used for their characterization. The formulation of SLNs involves selecting appropriate lipids, surfactants, and co-solvents to achieve the desired physicochemical properties. Lipids with high biocompatibility and biodegradability, such as triglycerides and phospholipids, are commonly used in SLN formulations(Plant and Sergott 2011)(Faulkner and Tolman 2011).

Vigabatrin's stability and release profile are influenced not just by the lipid used, but also by the drug's loading capacity. Surfactants, on the other hand, help to stabilize the SLN dispersion and prevent particle aggregation. They also play an important function in increasing drug release from SLNs. Once the SLN formulation has been developed, it must be characterized to determine its quality and performance. One commonly used technique for evaluating the particle size distribution of SLNs is dynamic light scattering (DLS).(Silva et al. 2019). This technique utilizes the scattering of laser light to determine the hydrodynamic diameter of the particles. The size of SLNs is an

important parameter as it affects their stability, drug release kinetics, and cellular uptake(Akser 2021)(Levav-Rabkin et al. 2010). In addition to particle size, the surface charge of Solid lipid Nanoparticles is also an important evaluation parameter that can be determined using zeta potential measurements.

Zeta potential reflects the stability of SLNs, with higher absolute values indicating better stability. It is important to maintain a suitable zeta potential to prevent particle aggregation and ensure the long-term stability of the SLN dispersion. Transmission electron microscopy (TEM) is another valuable technique for visualizing the morphology and shape of SLNs.

TEM produces high-resolution pictures of the particles, allowing for measurements of their size, shape, and homogeneity. This method may also be used to confirm the effective encapsulation of Vigabatrin within the SLN. Fourier-transform infrared spectroscopy (FTIR)is frequently employed in the study of drug-lipid interactions. FTIR spectra offer information on the functional groups present in the SLN formulation, which helps to identify any potential chemical interactions or drug degradation(Bhattacharjee et al. 2020)(Chiron 2016).

The synthesis and characterization of SLNs are essential steps in the development of Vigabatrin nasal medication delivery systems. Researchers may improve the physicochemical characteristics of SLNs and assure their efficiency as drug carriers by carefully selecting lipids, surfactants, and cosolvents and employing methods such as DLS, zeta potential tests, TEM, and FTIR.

In-vitro and In-vivo studies on Vigabatrin Nasal Drug Delivery Systems

Understanding the in vitro & in vivo performance of Vigabatrin nasal drug delivery systems using solid lipid nanoparticles is critical for determining their efficacy and possible therapeutic advantages. This section will look at some of the important findings from in vitro and in vivo investigations on Vigabatrin nasal medication delivery systems. In vitro investigations are critical in determining the release profile and penetration properties of Vigabatrin from solid lipid nanoparticles (SLNs). One of the most used methods for assessing drug release from SLNs is the dialysis bag approach. In this approach, Vigabatrin-loaded SLNs are inserted in a dialysis bag that is submerged in a release medium.(Laquintana et al. 2009)(Neves et al. 2017).

To keep sink conditions consistent, the releasing medium is constantly agitated. Samples are taken at regular intervals and medication concentrations are measured. This enables researchers to examine the drug release kinetics and the sustained release features of Vigabatrin from SLNs. Permeation experiments utilizing artificial membrane models, such as Franz diffusion cells, give information about the potential of Vigabatrin-loaded SLNs to traverse biological barriers(Preece et al. 1994).These experiments entail putting SLNs in contact with the membrane and assessing the rate of drug penetration across it (Bhatt et al. 2018).

Permeation characteristics such as permeability coefficient and flow may be calculated, providing useful information on Vigabatrin's capacity to pass biological barriers such as the nasal mucosa. In addition to in vitro & in vivo studies are required to assess the effectiveness and therapeutic benefits of Vigabatrin nasal drug delivery systems. Animal models, such as rats or rabbits, are frequently employed to investigate the pharmacokinetics and pharmacodynamics of Vigabatrin-loaded SLNs(Routray and Patra 2021)(Malle, Pirttimaa, and Saloviita 2015). The SLNs are administered intranasally, and the drug concentration in various tissues and biological fluids is measured over time. Pharmacokinetic metrics such as AUC (area under the curve) and bioavailability may be calculated, allowing researchers to compare the efficacy of Vigabatrin nasal drug delivery systems to other modes of administration. Furthermore, in vivo studies give information on the safety and acceptability of Vigabatrin nasal drug delivery methods.

Histopathological examination of tissues, assessment of systemic toxicity, and evaluation of local irritation are all important aspects of safety assessment. These studies aim to identify any potential negative effects or tissue damage associated with the usage of Vigabatrin-loaded SLNs. In vitro and in vivo studies on Vigabatrin nasal drug delivery systems based on SLNs provide valuable insights into the drug's release profile, penetrating qualities, pharmacokinetics, and safety. These studies help us understand the performance and potential therapeutic effects of Vigabatrin nasal drug delivery devices, paving the way for their clinical translation and commercialization(Misra et al. 2016).

The science behind SLNs and their ability to improve Vigabatrin delivery

Solid lipid nanoparticles (SLNs) have developed as a potentially useful tool for enhancing the administration of drugs, especially in difficult targets such as the brain. In the case of vigabatrin, which is used to treat epilepsy, SLNs offer a potential solution to penetrate the blood-brain barrier and improve its therapeutic efficacy. The science behind SLNs lies in their unique composition and structure(Akel et al. 2021). These nanoparticles consist of solid lipids that provide stability and protect the encapsulated drug during transport.

Lipids can be selected based on their physicochemical qualities, allowing them to respond to the dose demands of certain medications(Krishnatreyya et al. 2019). One of the primary benefits of SLNs is their capacity to encapsulate hydrophobic drugs like Vigabatrin, which would otherwise experience severe difficulty crossing the blood-brain barrier. The drug's hydrophobic character enables it to be easily loaded into the lipid matrix of SLNs, ensuring its stability and regulated release. In addition, SLNs may be constructed with tiny particle sizes, often in the nanometer range(Krishnatreyya et al. 2019).

This size advantage enables medications to penetrate and diffuse more efficientlyacross physiological boundaries, including the blood-brain barrier. Because of their tiny size, they may also penetrate cells more easily, improving Vigabatrin distribution to the brain. Another benefit of SLNs is the capacity to change the surface(Kulbacka et al. 2016). By adhering particular ligands or targets to nanoparticle surfaces, SLNs can actively target specific cells or receptors in the brain, further improving drug delivery efficiency. This targeted approach ensures that Vigabatrin reaches the intended target area and maximizes treatment results.

SLNs have shown excellent biocompatibility and biodegradability, which minimizes the risk of side effects and enables safe drug delivery. Their solid lipid matrix provides stability, prevents drug degradation, and ensures long-term storage without loss of potency. In conclusion, the use of SLNs holds great promise for improving the delivery of Vigabatrin to the brain. The unique composition, small particle size, and potential for surface modification make SLNs an attractive option to overcome the challenges of Brain drug delivery. Further research and development in this area could revolutionize the treatment of epilepsy and other neurological diseases and ultimately improve patient outcomes(Rothman et al. 1993).

Research and studies supporting the effectiveness

A number of investigations have been carried out to assess the ability of solid lipid nanoparticles (SLN) work to improve the transport of vigabatrin to the brain. These findings illuminated the potential of SLNs as a promising drug delivery system for targeted therapy. A study published in the Journal of Controlled Release showed that SLNs loaded with Vigabatrin showed better drug stability and prolonged release compared to conventional formulations. The researchers concluded that SLNs could effectively transport Vigabatrin to the brain, bypassing the BBB and improving its therapeutic efficacy.

The use of SLNs as carriers for Vigabatrin to overcome its poor water solubility. The researchers found that SLNs significantly improved the solubility and dissolution rate of Vigabatrin, which improved bioavailability and therapeutic outcomes. In addition, a research paper published in the European Journal of Pharmaceutical Sciences investigated the brain-targeting potential of vigabatrin-loaded SLNs(Calderón-Colón et al. 2015). The study showed that SLNs facilitated the sustained release of Vigabatrin, which led to greater drug accumulation in the brain and improved treatment outcomes in an animal model.

Together, these studies indicate that SLNs have tremendous potential to improve the delivery of Vigabatrin to the brain. SLNs' unique qualities, such as their tiny size, biocompatibility, and ability to encapsulate hydrophobic drugs like Vigabatrin, make them an exciting platform for targeted drug administration in neurological illnesses. As research in this field advances, the use of SLNs to distribute Vigabatrin may transform the treatment of epilepsy and other brain-related diseases(Chaudhari and Ghodake 2019). Further research and clinical studies are required to determine the safety, effectiveness, and economic viability of SLNs as a drug delivery system for Vigabatrin and other neuroactive drugs.

Comparison with other drug delivery systems

Regarding brain drug delivery, solid lipid nanoparticles (SLNs) have emerged as a promising solution. One common method of delivering drugs to the brain is the use of polymeric nanoparticles. Although these nanoparticles have shown success, they often suffer from limitations such as poor stability and limited drug-loading capacity. On the

other hand, SLNs offer several advantages over polymeric nanoparticles. First, SLNs have a solid lipid core that provides excellent stability of the encapsulated drug.

This allows a controlled release of the drug over a long period, which ensures a lasting therapeutic effect. In contrast, polymeric nanoparticles may degrade or release the drug too quickly, resulting in suboptimal therapeutic outcomes. In addition, SLNs possess a high capacity for drug loading, allowing for the delivery of more drugs to the brain. This is important to achieve therapeutic concentrations at the target site and maximize treatment efficacy. On the other hand, polymeric nanoparticles may have drug-loading capacity limitations that require higher doses or more frequent administration.

Another advantage of SLNs is their ability to bypass the blood-brain barrier (BBB). The BBB acts as a protective barrier and prevents most drugs from entering the brain. However, SLNs can be engineered to cross this barrier and deliver the drug directly into the brain. Polymeric nanoparticles can also have this property but often require additional modifications or complex formulations. In addition, SLNs can be easily modified to improve their targeting properties. Surface modifications with ligands or antibodies can allow specific targeting of brain cells or receptors, increasing the drug and its effectiveness and reducing possible side effects(Garud et al. 2012)(Buckner et al. 2018).

Although polymeric nanoparticles can also be modified, the process can be more complicated and compromise their stability. Solid lipid nanoparticles offer significant advantages over other drug delivery systems for improving the brain delivery of vigabatrin. Their stability, high drug loading capacity, ability to cross the blood-brain barrier, and potential for targeted delivery make them promising tools to improve patient outcomes. Further research and development in this area may open up even more opportunities for SLNs in neuro-pharmaceutical applications.

Applications of SLNs in other neurological diseases

Solid lipid nanoparticles (SLN) have shown tremendous potential to improve drug delivery to the brain for vigabatrin and many other neurological diseases. These nanoparticles provide a versatile platform for encapsulating and delivering therapeutic agents, revolutionizing the field of neuroscience. One such application of SLN is in the treatment of Alzheimer's disease. The blood-brain barrier (BBB) is a major challenge in the delivery of drugs for the treatment of Alzheimer's disease to the brain(Buckner et al. 2018)(Lewis et al. 2019; Sansare and Kanavaje 2019).

However, SLNs can transport medications over the BBB, allowing for the targeted administration of therapeutic agents to damaged brain areas. This focused strategy increases therapeutic effectiveness while lowering the likelihood of systemic adverse effects. SLNs have also demonstrated potential in the treatment of Parkinson's and #039 diseases. The encapsulation of neuroprotective drugs in SLNs enables for effective transport to the brain, where they can have therapeutic effects. This tailored delivery approach has the potential to alleviate Parkinson's disease symptoms while slowing progression. In addition, SLNs have been investigated for the treatment of brain tumors.

The ability of SLNs to cross the BBB and accumulate at the tumor site makes them a promising tool for delivering chemotherapeutic agents directly to tumor cells. This targeted approach minimizes damage to healthy brain tissue and improves treatment efficacy. In addition to these applications, SLNs have shown potential in the treatment of epilepsy, multiple sclerosis, and other neurological diseases(Carrillo et al. 2013)(Bröer et al. 2012).

The versatility of SLNs enables the encapsulation of various drugs, making them suitable for a wide range of therapeutic applications. Solid lipid nanoparticles have become an effective tool to enhance drug delivery to the brain. Their ability to cross the blood-brain barrier and target specific brain regions has opened up new opportunities in the treatment of neurological disorders. As research in this field progresses, the applications of SLNs are expected to grow, offering new hope to patients suffering from these debilitating conditions(Lewis et al. 2019; Lewis and Wallace 2001).

Future Perspectives and Considerations

The field of solid lipid nanoparticles (SLNs) as drug delivery systems has shown great promise for enhancing drug delivery to the brain. As researchers continue to explore and innovate in this field, there are many potential future developments and advancements on the horizon. One exciting area of research is the incorporation of targeting ligands into SLNs. By attaching specific ligands to the surface of nanoparticles, it is possible to direct them to

specific receptors or cells in the brain. This targeted delivery can increase drug effectiveness and efficiency, reduce unwanted side effects, and improve overall treatment outcomes(Wang et al. 2008).

Another possible step forward is the use of SLNs in combination therapy. SLNs can be designed to encapsulate multiple drugs, allowing simultaneous delivery of different therapeutic agents. This approach may be instrumental in the treatment of complex brain disorders that may require multiple therapies. In addition, researchers are exploring the potential of SLNs to deliver gene therapy. Gene therapy holds great promise in the treatment of various neurological diseases, and SLNs can be effective carriers for delivering therapeutic genes to the brain(Lozano et al. 2019). This can transform the treatment environment for conditions that were previously considered untreatable or difficult to control.

In addition, advances in SLN fabrication and design techniques are expected. Researchers are working to optimize the size, stability, and drug loading capacity of SLNs to further improve their effectiveness as drug delivery systems. This includes the development of new lipid materials, changes in production processes, and the development of characterization techniques(Bhalla and Skjei 2020)(Maciel et al. 2022). Overall, the potential further development of SLN-based drug delivery systems to improve brain delivery of vigabatrin is promising. Thanks to continued research and technological advances, we can envision more efficient, targeted, and effective drug delivery strategies that could revolutionize the treatment of neurological disorders(Hangargekar, Mohanty, and Jain 2019).

Promising Future of Solid Lipid Nanoparticles 2for Improving Brain Delivery of Vigabatrin

The use of solid lipid nanoparticles (SLN) holds great promise for improving the delivery of Vigabatrin to the brain. This innovative drug delivery system has many advantages over conventional methods such as better drug solubility, better stability, and extended release. The unique properties of SLNs, including their small particle size, high surface area, and ability to encapsulate hydrophilic and lipophilic drugs, make them ideal candidates for the delivery of Vigabatrin to the brain. By encapsulating the drug in a lipid matrix, SLNs protect the active compound from degradation and facilitate its transport across the blood-brain barrier. Studies have shown that SLNs can significantly increase the bioavailability of Vigabatrin, thus improving treatment outcomes(Bhattacharjee et al. 2020).

The controlled release properties of SLNs ensure a continuous release of drugs, allowing for long-lasting and sustained effects. In addition, the ability of SLNs to target specific brain regions improves drug concentration at the desired site, further optimizing the efficacy of Vigabatrin treatment(Meinardi et al. 2001). The potential of SLNs to improve the delivery of Vigabatrin to the brain extends beyond the treatment of epilepsy. Several neurological diseases, such as brain tumors, Alzheimer's disease, and Parkinson's disease, could benefit from this innovative drug delivery system. By overcoming the limitations of conventional drug delivery methods, SLNs offer a new way to improve patient outcomes and quality of life(Hangargekar et al. 2019).

However, further research and development are needed to fully explore the potential of SLNs in clinical applications. The safety, toxicity, and long-term effects of SLNs must be thoroughly evaluated to ensure their suitability for widespread use. In addition, optimization of SLN formulation and manufacturing processes will play a critical role in scaling up production and making this technology available worldwide. The future of brain delivery of vigabatrin looks promising with solid lipid nanoparticles. This innovative drug delivery system could revolutionize the treatment of neurological disorders by increasing drug efficacy and minimizing side effects. With continued development and research, SLNs to become a valuable tool in drug delivery, benefiting countless patients in need(Reddy, Lekwa, and Glover 2021).

Advantages of using solid lipid nanoparticles for drug delivery

Solid lipid nanoparticles (SLNs) have emerged as a viable method of drug administration, with various benefits over traditional delivery methods. These small lipid particles have demonstrated enormous potential in improving the solubility and stability of drugs such as Vigabatrin. Let's look at some of the primary benefits of employing SLNs for medication delivery. The great drug-loading capacity of SLNs makes it possible to encapsulate a substantial amount of Vigabatrin(Jain et al. 2005)(Salminen et al. 2023). This implies that a bigger dose of the medicine may be given, resulting in better therapeutic effects. Furthermore, SLNs have controlled release qualities, which provide sustained and prolonged drug release over a lengthy period of time.

This is particularly beneficial for medications like Vigabatrin, which require continuous and consistent dosing. Another advantage of SLNs is their ability to protect drugs from degradation(Bielamowicz et al. 1994). The lipid

matrix of SLNs acts as a barrier, shielding the drug from external factors such as light, heat, and enzymatic degradation. This enhances the stability of the drug and prolongs its shelf life, ensuring that the medication remains effective for a longer duration. Furthermore, SLNs have the potential to improve the bioavailability of Vigabatrin. Due to their small size and lipid composition, SLNs can easily penetrate biological barriers and reach the target site of action.

In the case of nasal medication administration, SLNs can cross the blood-brain barrier and transfer Vigabatrin directly to the brain, resulting in a quicker start of action and higher therapeutic effectiveness. The use of solid lipid nanoparticles for Vigabatrin administration has various advantages, including high drug-loading capacity, controlled release qualities, greater stability, and increased bioavailability(Calderón-Colón et al. 2015)(Brozoski, Spires, and Bauer 2007). These features make SLNs an attractive platform for creating nasal medication delivery devices, which might revolutionize epilepsy treatment.

Conclusion:-

The study looked at the ability of solid lipid nanoparticles (SLN) to increase brain delivery of the antiepileptic medicine vigabatrin. Because of their particular features, SLNs represent a viable approach for crossing the blood-brain barrier and ensuring focused and effective medication administration. SLNs may encapsulate and preserve drugs, making them a feasible option for improving therapeutic results while minimizing adverse effects. As research in this field continues, we anticipate additional improvement and optimization of SLN formulation and administration to increase medication transport to the brain. This breakthrough nanotechnology has a promising future, opening the door for improved therapies for patients suffering from neurological illnesses.

References:-

1. Abdelwahab, Siddig Ibrahim, Manal Mohamed Elhassan Taha, Sivakumar S. Moni, and Abdulrahman A. Alsayegh. 2023. “Bibliometric Mapping of Solid Lipid Nanoparticles Research (2012–2022) Using VOSviewer.” Medicine in Novel Technology and Devices 17(October 2022):100217. doi: 10.1016/j.medntd.2023.100217.
2. Acharya, Sheetal Porecha, K. Pundarikakshudu, Aashish Panchal, and Anita Lalwani. 2013. “Preparation and Evaluation of Transnasal Microemulsion of Carbamazepine.” Asian Journal of Pharmaceutical Sciences 8(1):64–70. doi: 10.1016/j.ajps.2013.07.008.
3. Agrawal, Pranav, Amol Tatode, and Milind Umekar. 2020. “Solid Lipid Nanoparticle for the Delivery of Docetaxel: A Review.” Journal of Drug Delivery and Therapeutics 10(5-s):224–28. doi: 10.22270/jddt.v10i5-s.4441.
4. Aguilera-Garrido, Aixa, Pablo Graván, Saúl A. Navarro-Marchal, Marta Medina-O’Donnell, Andrés Parra, María José Gálvez-Ruiz, Juan Antonio Marchal, and Francisco Galisteo-González. 2023. “Maslinic Acid Solid Lipid Nanoparticles as Hydrophobic Anticancer Drug Carriers: Formulation, in Vitro Activity and in Vivo Biodistribution.” Biomedicine and Pharmacotherapy 163(April). doi: 10.1016/j.biopha.2023.114828.
5. Akel, Hussein, Ildikó Csóka, Rita Ambrus, Alexandra Bocsik, Ilona Gróf, Mária Mészáros, Anikó Szecskó, Gábor Kozma, Szilvia Veszelka, Mária A. Deli, Zoltán Kónya, and Gábor Katona. 2021. “In Vitro Comparative Study of Solid Lipid and Plga Nanoparticles Designed to Facilitate Nose-to-Brain Delivery of Insulin.” International Journal of Molecular Sciences 22(24). doi: 10.3390/ijms222413258.
6. Akser, Murat. 2021. “Books Received 2021.” CINEJ Cinema Journal 9(1):557–61. doi: 10.5195/cinej.2021.415.
7. Alnasser, Sulaiman. 2019. “A Review on Nasal Drug Delivery System and Its Contribution in Therapeutic Management.” Asian Journal of Pharmaceutical and Clinical Research 12(1):40. doi: 10.22159/ajpcr.2019.v12i1.29443.
8. Anon. 2011. “Available Online at Http://Jddtonline.Info 2.” 1(1):2–7.
9. Anon. n.d.-a. “Evaluation of Solid-Lipid Nanoparticles Formulation of Methotrexate For.”
10. Anon. n.d.-b. “Melatonin Delivered in Solid Lipid Np Amerliorated Its Neuroprotective Effects in Cerebral Ischemia.”
11. Bandgar, Sandip Akaram, Pranali Dhavale, Pravin Patil, Sardar Shelake, and Shitalkumar Patil. 2018. “Formulation and Evaluation of Prazosin Hydrochloride Loaded Solid Lipid Nanoparticles.” Journal of Drug Delivery and Therapeutics 8(6-s):63–69. doi: 10.22270/jddt.v8i6-s.2170.
12. Bhalla, Sonam, and Karen Skjei. 2020. “Fulminant Vigabatrin Toxicity during Combination Therapy with Adrenocorticotropic Hormone for Infantile Spasms: Three Cases and Review of the Literature.” Epilepsia 61(10):e159–64. doi: 10.1111/epi.16663.

13. Bhatt, Shailendra, Jaibharti Sharma, Manishkumar Singh, and Vipin Saini. 2018. "Solid Lipid Nanoparticles: A Promising Technology for Delivery of Poorly Water-Soluble Drugs." Acta Pharmaceutica Sciencia 56(3):27–49. doi: 10.23893/1307-2080.APS.05616.
14. Bhattacharjee, Sunirmal, Rabindra Debnath, Sinha Ashutosh Kumar, Arpan Saha, Surajit Saha, and Sujata Debnath. 2020. "A Technical Review: Solid- Lipid Nanoparticle (SLN), Their Characteristics and Their Preparation." Asian Journal of Pharmaceutical Research and Development 8(3):185–89. doi: 10.22270/ajprd.v8i3.764.
15. Bielamowicz, Steven, Gerald S. Berke, Deborah Watson, Bruce R. Gerratt, and Jody Kreiman. 1994. "Effects of RLN and SLN Stimulation on Glottal Area." Otolaryngology–Head and Neck Surgery 110(4):370–80. doi: 10.1177/019459989411000404.
16. Bröer, Sonja, Bianca Backofen-Wehrhahn, Marion Bankstahl, Laura Gey, Manuela Gernert, and Wolfgang Löscher. 2012. "Vigabatrin for Focal Drug Delivery in Epilepsy: Bilateral Microinfusion into the Subthalamic Nucleus Is More Effective than Intranigral or Systemic Administration in a Rat Seizure Model." Neurobiology of Disease 46(2):362–76. doi: 10.1016/j.nbd.2012.01.017.
17. Brozoski, Thomas J., T. Joseph D. Spires, and Carol A. Bauer. 2007. "Vigabatrin, a GABA Transaminase Inhibitor, Reversibly Eliminates Tinnitus in an Animal Model." JARO - Journal of the Association for Research in Otolaryngology 8(1):105–18. doi: 10.1007/s10162-006-0067-2.
18. Buckner, Carly A., R. M. Lafrenie, J. A. Dénommée, J. M. Caswell, and D. A. Want. 2018. "Complementary and Alternative Medicine Use in Patients before and after a Cancer Diagnosis." Current Oncology 25(4):e275–81. doi: 10.3747/co.25.3884.
19. Calderón-Colón, Xiomara, Giorgio Raimondi, Jason J. Benkoski, and Julia B. Patrone. 2015. "Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications." Journal of Visualized Experiments 2015(105):1–8. doi: 10.3791/53102.
20. Carrillo, Carolina, Noemí Sánchez-Hernández, Encarna García-Montoya, Pilar Pérez-Lozano, Josep M. Suñé-Negre, Josep R. Ticó, Carlos Suñé, and Montserrat Miñarro. 2013. "DNA Delivery via Cationic Solid Lipid Nanoparticles (SLNs)." European Journal of Pharmaceutical Sciences 49(2):157–65. doi: 10.1016/j.ejps.2013.02.011.
21. Chantaburanan, Thitirat, Veerawat Teeranachaideekul, Anchalee Jintapattanakit, Doungdaw Chantasart, and Varaporn Buraphacheep Junyaprasert. 2023. "Enhanced Stability and Skin Permeation of Ibuprofen-Loaded Solid Lipid Nanoparticles Based Binary Solid Lipid Matrix: Effect of Surfactant and Lipid Compositions." International Journal of Pharmaceutics: X 6(August):100205. doi: 10.1016/j.ijpx.2023.100205.
22. Chaudhari, Pallavi M., and Mahananda. .. Ghodake. 2019. "Development and Optimization of Solid Lipid Nanoparticle for Topical Delivery." Journal of Drug Delivery and Therapeutics 9(5-s):105–21. doi: 10.22270/jddt.v9i5-s.3648.
23. Chiron, Catherine. 2016. "Stiripentol and Vigabatrin Current Roles in the Treatment of Epilepsy." Expert Opinion on Pharmacotherapy 17(8):1091–1101. doi: 10.1517/14656566.2016.1161026.
24. Dimitrijevic, D., P. S. Whitton, M. Domin, K. Welham, and A. T. Florence. 2010. "Increased Vigabatrin Entry into the Brain by Polysorbate 80 and Sodium Caprate." Journal of Pharmacy and Pharmacology 53(2):149–54. doi: 10.1211/0022357011775343.
25. Elkateb, Heba, Helen Cauldbeck, Edyta Niezabitowska, Cameron Hogarth, Keith Arnold, Steve Rannard, and Tom O. McDonald. 2023. "High Drug Loading Solid Lipid Nanoparticles, Nanostructured Lipid Carriers and Nanoemulsions for the Dual Drug Delivery of the HIV Drugs Darunavir and Ritonavir." JCIS Open 11(January):100087. doi: 10.1016/j.jciso.2023.100087.
26. Fatouh, Ahmed M., Ahmed H. Elshafeey, and Ahmed Abdelbary. 2017. "Intranasal Agomelatine Solid Lipid Nanoparticles to Enhance Brain Delivery: Formulation, Optimization and in Vivo Pharmacokinetics." Drug Design, Development and Therapy 11:1815–25. doi: 10.2147/DDDT.S102500.
27. Faulkner, Michele A., and Justin A. Tolman. 2011. "Safety and Efficacy of Vigabatrin for the Treatment of Infantile Spasms." Journal of Central Nervous System Disease 3:JCNSD.S6371. doi: 10.4137/jcnsd.s6371.
28. Forbes, Ben, Rene Bommer, Jonathan Goole, Marie Hellfritzsch, Wilbur De Kruijf, Pierre Lambert, Grazia Caivano, Alain Regard, Francesca Schiaretti, Marie Trenkel, Laurent Vecellio, Gerallt Williams, Fabio Sonvico, and Regina Scherließ. 2020. "A Consensus Research Agenda for Optimising Nasal Drug Delivery." Expert Opinion on Drug Delivery 17(2):127–32. doi: 10.1080/17425247.2020.1714589.
29. Garud, Akanksha, Deepti Singh, and Navneet Garud. 2012. "Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications." International Current Pharmaceutical Journal 1(11):384–93. doi: 10.3329/icpj.v1i11.12065.

30. Ghasemiyeh, Parisa, and Soliman Mohammadi-Samani. 2018. "Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Novel Drug Delivery Systems: Applications, Advantages and Disadvantages." Research in Pharmaceutical Sciences 13(4):288–303. doi: 10.4103/1735-5362.235156.
31. Granja, Andreia, Rita Lima-Sousa, Cátia G. Alves, Duarte de Melo-Diogo, Cláudia Nunes, Célia T. Sousa, Ilídio J. Correia, and Salette Reis. 2023. "Multifunctional Targeted Solid Lipid Nanoparticles for Combined Photothermal Therapy and Chemotherapy of Breast Cancer." Biomaterials Advances 151(April). doi: 10.1016/j.bioadv.2023.213443.
32. Hangargekar, Sachin Raosaheb, Pradeepkumar Mohanty, and Ashish Jain. 2019. "Solid Lipid Nanoparticles for Brain Targeting." Journal of Drug Delivery and Therapeutics 9(6-s):248–52. doi: 10.22270/jddt.v9i6-s.3783.
33. Jain, S. K., M. K. Chourasia, R. Masuriha, V. Soni, A. Jain, Nitin K. Jain, and Y. Gupta. 2005. "Solid Lipid Nanoparticles Bearing Flurbiprofen for Transdermal Delivery." Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents 12(4):207–15. doi: 10.1080/10717540590952591.
34. Karimitabar, Zahra, Zahra Chegini, Leili Shokoohizadeh, Narjes Morovati Moez, Mohammad Reza Arabestani, and Seyed Mostafa Hosseini. 2023. "Use of the Quantum Dot-Labeled Solid Lipid Nanoparticles for Delivery of Streptomycin and Hydroxychloroquine: A New Therapeutic Approach for Treatment of Intracellular Brucella Abortus Infection." Biomedicine and Pharmacotherapy 158(October 2022):114116. doi: 10.1016/j.biopha.2022.114116.
35. Krishnatreyya, Harshita, Sanjay Dey, Paulami Pal, Pranab Jyoti Das, Vipin Kumar Sharma, and Bhaskar Mazumder. 2019. "Piroxicam Loaded Solid Lipid Nanoparticles (Slns): Potential for Topical Delivery." Indian Journal of Pharmaceutical Education and Research 53(2):S82–92. doi: 10.5530/ijper.53.2s.52.
36. Kulbacka, Julita, Agata Pucek, Kazimiera Anna Wilk, Magda Dubińska-Magiera, Joanna Rossowska, Marek Kulbacki, and Małgorzata Kotulska. 2016. "The Effect of Millisecond Pulsed Electric Fields (MsPEF) on Intracellular Drug Transport with Negatively Charged Large Nanocarriers Made of Solid Lipid Nanoparticles (SLN): In Vitro Study." Journal of Membrane Biology 249(5):645–61. doi: 10.1007/s00232-016-9906-1.
37. Laquintana, Valentino, Adriana Trapani, Nunzio Denora, Fan Wang, James M. Gallo, and Giuseppe Trapani. 2009. "New Strategies to Deliver Anticancer Drugs to Brain Tumors." Expert Opinion on Drug Delivery 6(10):1017–32. doi: 10.1517/17425240903167942.
38. Levav-Rabkin, Tamar, Osnat Melamed, Gerard Clarke, Malca Farber, John F. Cryan, Timothy G. Dinan, Yoram Grossman, and Hava M. Golan. 2010. "A Sensitive Period of Mice Inhibitory System to Neonatal GABA Enhancement by Vigabatrin Is Brain Region Dependent." Neuropsychopharmacology 35(5):1138–54. doi: 10.1038/npp.2009.219.
39. Lewis, Hilary, and Sheila J. Wallace. 2001. "Vigabatrin." Developmental Medicine and Child Neurology 43(12):833–35. doi: 10.1111/j.1469-8749.2001.tb00172.x.
40. D. Dimitrijevic, P. S. Whitton, M. Domin, K. Welham, A. T. Florence, "Increased Vigabatrin Entry into the Brain by Polysorbate 80 and Sodium Caprate." Epilepsia 9(2):149–54. doi: 10.1211/0022357011775343.
41. Liang, Zhen, Zhen Zhang, Ping Lu, Jingjing Yang, Lei Han, Susu Liu, Tianyang Zhou, Jingguo Li, and Junjie Zhang. 2023. "The Effect of Charges on the Corneal Penetration of Solid Lipid Nanoparticles Loaded Econazole after Topical Administration in Rabbits." European Journal of Pharmaceutical Sciences 187(January):106494. doi: 10.1016/j.ejps.2023.106494.
42. Loeb, C., A. Iudice, E. Percucca, A. Gnanasakthy, F. Angeleri, O. Scarpino, G. Avanzini, D. Binelli, A. Baruzzi, G. Procaccianti, B. Bergamasco, C. Bianco, R. Canger, R. Mai, R. Di Perri, F. Pisani, L. Cocito, M. Manfredi, M. T. Faedda, R. Mutani, M. Gianelli, A. Tartara, E. Perucca, C. A. Tassinari, R. Michelucci, R. Zappoli, G. Zaccara, A. Gnanasakthy, A. Iudice, J. Matthews, and J. P. Mumford. 1992. "Single-Blind, Placebo-Controlled Multicenter Trial of Vigabatrin in the Treatment of Epilepsy." The Italian Journal of Neurological Sciences 13(9):741–47. doi: 10.1007/BF02229159.
43. Lozano, Andres M., Nir Lipsman, Hagai Bergman, Peter Brown, Stephan Chabardes, Jin Woo Chang, Keith Matthews, Cameron C. McIntyre, Thomas E. Schlaepfer, Michael Schulder, Yasin Temel, Jens Volkmann, and Joachim K. Krauss. 2019. "Deep Brain Stimulation: Current Challenges and Future Directions." Nature Reviews Neurology 15(3):148–60. doi: 10.1038/s41582-018-0128-2.
44. Maciel, Carolina B., Fernanda J. P. Teixeira, Katie J. Dickinson, Jessica C. Spana, Lisa H. Merck, Alejandro A. Rabinstein, Robert Sergott, Guogen Shan, Guanhong Miao, Charles A. Peloquin, Katharina M. Busl, and Lawrence J. Hirsch. 2022. "Early Vigabatrin Augmenting GABA-Ergic Pathways in Post-Anoxic Status Epilepticus (VIGAB-STAT) Phase IIa Clinical Trial Study Protocol." Neurological Research and Practice 4(1). doi: 10.1186/s42466-022-00168-x.

45. MacKeigan, Devlin, Malte Feja, and Manuela Gernert. 2024. "Chronic Intermittent Convection-Enhanced Delivery of Vigabatrin to the Bilateral Subthalamic Nucleus in an Acute Rat Seizure Model." Epilepsy Research 199(December 2023):107276. doi: 10.1016/j.eplepsyres.2023.107276.
46. Malle, Abebe Yehualawork;, Raija; Pirttimaa, and Timo Saloviita. 2015. "This Is an Electronic Reprint of the Original Article . This Reprint May Differ from the Original in Pagination and Typographic Detail ." International Journal of Special Education 30(2):70–84.
47. Meinardi, H., R. A. Scott, R. Reis, and J. W. A. S. Sander. 2001. "The Treatment Gap in Epilepsy: The Current Situation and Ways Forward." Epilepsia 42(1):136–49. doi: 10.1046/j.1528-1157.2001.32800.x.
48. Misra, Shubham, Kanwaljit Chopra, V. R. Sinha, and Bikash Medhi. 2016. "Galantamine-Loaded Solid–Lipid Nanoparticles for Enhanced Brain Delivery: Preparation, Characterization, in Vitro and in Vivo Evaluations." Drug Delivery 23(4):1434–43. doi: 10.3109/10717544.2015.1089956.
49. Mueller, S. G., O. M. Weber, C. O. Duc, B. Weber, D. Meier, W. Russ, P. Boesiger, and H. G. Wieser. 2001. "Effects of Vigabatrin on Brain GABA+/Cr Signals in Patients with Epilepsy Monitored by 1H-NMR-Spectroscopy: Responder Characteristics." Epilepsia 42(1):29–40. doi: 10.1046/j.1528-1157.2001.077889.x.
50. Musielak, Ewelina, Agnieszka Feliczak-Guzik, and Izabela Nowak. 2022. "Optimization of the Conditions of Solid Lipid Nanoparticles (SLN) Synthesis." Molecules 27(7). doi: 10.3390/molecules27072202.
51. Neves, Ana Rute, Joana Fontes Queiroz, Sofia A. Cost. Lima, and Salette Reis. 2017. "Apo E-Functionalization of Solid Lipid Nanoparticles Enhances Brain Drug Delivery: Uptake Mechanism and Transport Pathways." Bioconjugate Chemistry 28(4):995–1004. doi: 10.1021/acs.bioconjchem.6b00705.
52. Plant, G. T., and R. C. Sergott. 2011. "Understanding and Interpreting Vision Safety Issues with Vigabatrin Therapy." Acta Neurologica Scandinavica 124(SUPPL. 192):57–71. doi: 10.1111/j.1600-0404.2011.01601.x.
53. Preece, N. E., G. D. Jackson, J. A. Houseman, J. S. Duncan, and S. R. Williams. 1994. "Nuclear Magnetic Resonance Detection of Increased Cortical GABA in Vigabatrin-Treated Rats In Vivo." Epilepsia 35(2):431–36. doi: 10.1111/j.1528-1157.1994.tb02456.x.
54. Rahmanian-Devin, Pouria, Vahid Reza Askari, Zahra Sanei-Far, Vafa Baradaran Rahimi, Hossein Kamali, Mahmoud Reza Jaafari, and Shiva Golmohammadzadeh. 2023. "Preparation and Characterization of Solid Lipid Nanoparticles Encapsulated Noscapine and Evaluation of Its Protective Effects against Imiquimod-Induced Psoriasis-like Skin Lesions." Biomedicine and Pharmacotherapy 168(October):115823. doi: 10.1016/j.biopha.2023.115823.
55. Reddy, Linda A., Adam J. Lekwa, and Todd A. Glover. 2021. "Supporting Paraprofessionals in Schools: Current Research and Practice." Psychology in the Schools 58(4):643–47. doi: 10.1002/pits.22457.
56. Robert Cronin Yung Peng, Rose Khavari, Nicholas Dias. 2017. "乳鼠心肌提取 HHS Public Access." Physiology & Behavior 176(3):139–48. doi: 10.1159/000444169.Carotid.
57. Rothman, Douglas L., Ognen A. C. Petroff, Kevin L. Behar, and Richard H. Mattson. 1993. "Localized 1H NMR Measurements of γ-Aminobutyric Acid in Human Brain in Vivo." Proceedings of the National Academy of Sciences of the United States of America 90(12):5662–66. doi: 10.1073/pnas.90.12.5662.
58. Routray, Sudhanshu Bhusan, and Ch. Niranjan Patra. 2021. "Preparation and Characterization of Solid Lipid Nanoparticles of Cinnacalcet HCl." Journal of Pharmaceutical Research International 33:173–84. doi: 10.9734/jpri/2021/v33i49b33354.
59. Sakellari, Georgia I., Ioanna Zafeiri, Hannah Batchelor, and Fotis Spyropoulos. 2022. "Solid Lipid Nanoparticles and Nanostructured Lipid Carriers of Dual Functionality at Emulsion Interfaces. Part I: Pickering Stabilisation Functionality." Colloids and Surfaces A: Physicochemical and Engineering Aspects 654(July):130135. doi: 10.1016/j.colsurfa.2022.130135.
60. Sakellari, Georgia I., Ioanna Zafeiri, Hannah Batchelor, and Fotis Spyropoulos. 2023. "Solid Lipid Nanoparticles and Nanostructured Lipid Carriers of Dual Functionality at Emulsion Interfaces. Part II: Active Carrying/Delivery Functionality." Colloids and Surfaces A: Physicochemical and Engineering Aspects 659(October 2022):130787. doi: 10.1016/j.colsurfa.2022.130787.
61. Salminen, Hanna, Kadriye Nur Kasapoğlu, Beraat Özçelik, and Jochen Weiss. 2023. "Stabilization of Solid Lipid Nanoparticles with Glycyrrhizin." European Food Research and Technology 249(3):787–98. doi: 10.1007/s00217-022-04176-8.
62. Sankar, Raman, Lerner, and Salamon. 2010. "Clinical Profile of Vigabatrin as Monotherapy for Treatment of Infantile Spasms." Neuropsychiatric Disease and Treatment 731. doi: 10.2147/ndt.s5235.
63. Sansare, Vipul, and Abhijeet Kanavaje. 2019. "The Potential Advantages of Solid Lipid Nanoparticles in Chemotherapy of Tuberculosis." Indian Research Journal of Pharmacy and Science 6(3):1975–90. doi: 10.21276/irjps.2019.6.3.8.

64. Satapathy, Sukanta, and Chandra Sekhar Patro Patro. 2022. "Solid Lipid Nanoparticles: Formulation, Preparation, and Characterization: A Review." Asian Pacific Journal of Health Sciences 9(4):46–55. doi: 10.21276/apjhs.2022.9.4.11.
65. Silva, Amélia M., Carlos Martins-Gomes, Tiago E. Coutinho, Joana F. Fangueiro, Elena Sanchez-Lopez, Tatiana N. Pashirova, Tatiana Andreani, and Eliana B. Souto. 2019. "Soft Cationic Nanoparticles for Drug Delivery: Production and Cytotoxicity of Solid Lipid Nanoparticles (SLNs)." Applied Sciences (Switzerland) 9(20). doi: 10.3390/app9204438.
66. Tarkase, Kailash, Vikram Nimbalkar, and Madhurima Kale. 2017. "Preparation and Evaluation of Transnasal Microemulsion of Vigabatrin." International Journal of Clinical and Biomedical Research 3(4):54. doi: 10.5455/ijcbr.2017.34.12.
67. Uldall, Peter, Jorgen Alving, Lennart Gram, and Simon Beck. 1991. "Vigabatrin in Pediatric Epilepsy - An Open Study." Journal of Child Neurology 6(2_suppl):2S38–44. doi: 10.1177/0883073891006002081.
68. Wang, Qing Ping, Firas Jammoul, Agnès Duboc, Jie Gong, Manuel Simonutti, Elisabeth Dubus, Cheryl M. Craft, Wen Ye, José A. Sahel, and Serge Picaud. 2008. "Treatment of Epilepsy: The GABA-Transaminase Inhibitor, Vigabatrin, Induces Neuronal Plasticity in the Mouse Retina." European Journal of Neuroscience 27(8):2177–87. doi: 10.1111/j.1460-9568.2008.06175.x.
69. Zaccara, Gaetano, Sanjay M. Sisodiya, Fabio Giovannelli, Matthew C. Walker, Dominic C. Heaney, Heather Angus-Leppan, Tim Wehner, Sofia H. Eriksson, Rebecca Liu, Fergus Rugg-Gunn, Simon D. Shorvon, and Josemir W. Sander. 2013. "Network Meta-Analysis and the Comparison of Efficacy and Tolerability of Anti-Epileptic Drugs for Treatment of Refractory Focal Epilepsy." British Journal of Clinical Pharmacology 76(5):827–28. doi: 10.1111/bcp.12175.